INTERVIEW: Islet Sciences touts novel early diabetes test
This article was originally published in Clinica
Executive Summary
Currently, most people with Type 1 diabetes are not diagnosed until the disease has already been progressing unchecked for some time. “Generally, you don’t know you have it until you have these more dramatic hyper- and hypo- uncontrolled glycemic events,” Islet Sciences CEO James Green told Clinica. “It can be pretty frightening, especially as a lot of these patients are children.”
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.